CMP Pharma

Founded in 1975, CMP Pharma is a legacy pharmaceutical company dedicated to creating customized oral liquid and topical formulations for patients underserved by traditional solid dosage forms, particularly in acute and long-term care settings. The company has achieved significant milestones with FDA approvals for novel liquid formulations of established drugs, including Norliqva (amlodipine), Tadliq (tadalafil), and CaroSpir (spironolactone). CMP's strategy centers on identifying niche therapeutic markets, developing high-value alternative dosage forms, and manufacturing products at its facility in Farmville, North Carolina, for distribution to hospitals, long-term care facilities, and retail channels.

Specialized expertise in the formulation, development, and manufacturing of FDA-approved oral liquid suspensions/solutions and semi-solid topical products, focusing on creating bioequivalent alternative dosage forms for patients with swallowing difficulties.

CMP's main competitors are the standard solid oral dosage forms of the drugs they liquefy and compounding pharmacies. Their primary differentiation is being the first and only FDA-approved source for these specific liquid formulations, offering guaranteed consistency, quality, and regulatory compliance that compounding cannot match.